← Back to Search

Non-invasive Brain Stimulation

rTMS for Treatment-Resistant Depression

N/A

Recruiting

Research Sponsored by Sunnybrook Health Sciences Centre

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 years

Awards & highlights

Study Summary

This trial will examine if severe depression has a different brain signature and if TMS can help treat those patients who don't respond to other treatments.

Who is the study for?

This trial is for adults aged 20-65 with severe, long-lasting depression that hasn't improved after trying at least six different antidepressants and other treatments like psychotherapy or ECT. They must have a specific score on a depression rating scale to qualify. People can't join if they're pregnant, unable to consent, have MRI contraindications, other major medical/psychiatric issues not related to depression, history of psychosis or substance dependence recently.Check my eligibility

What is being tested?

The study tests an 'accelerated' rTMS protocol using brain imaging before treatment. It aims to see if those with ultra-treatment resistant depression respond differently than those with less severe cases and whether this intense one-week rTMS treatment can help where surgery might be the next option.See study design

What are the potential side effects?

rTMS may cause discomfort at the site of stimulation, headache, lightheadedness, or seizures in rare cases. Most side effects are mild and improve shortly after each session.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Imaging

Trial Design

1Treatment groups

Experimental Treatment

Group I: Accelerated iTBS treatmentExperimental Treatment1 Intervention

accelerated iTBS treatment protocol over 5 consecutive days

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

rTMS

2016

Completed Phase 3

~840

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Sunnybrook Health Sciences CentreLead Sponsor

656 Previous Clinical Trials

1,551,250 Total Patients Enrolled

36 Trials studying Depression

9,526 Patients Enrolled for Depression

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are any individuals over 50 years of age currently being considered for participation in this clinical experiment?

"This trial specifically calls for participants between the ages of 20 and 65. There are 120 studies open to those younger than 18, while 647 studies have been made available for individuals older than 65."

Answered by AI

Are there remaining opportunities for participants to join this clinical trial?

"According to the latest information available on clinicaltrials.gov, this trial is still searching for candidates. The study was first posted in late September of 2023 and was updated at the end of October that same year."

Answered by AI

How many individuals are partaking in this clinical experiment?

"Affirmative. As per the information hosted on clinicaltrials.gov, this research is presently seeking participants - initially posted on September 27th of 2023 and most recently updated October 31st of 2023. The study requires 58 individuals from a single site to participate."

Answered by AI

Is enrollment open for the current research project?

"This clinical trial is enlisting 58 individuals afflicated with depression, aged between 20 and 65. To qualify for inclusion in this study, applicants must meet the following criteria: age (20-65), a diagnosis of MDD or persistent depressive disorder meeting DSM 5.0 requirements along with an HRSD-17 score of 18 or higher; those suffering from treatment resistant depression will need to have experienced failure on >6 antidepressants as well as at least one adjunctive antidepressant medication that was administered correctly; psychotherapy attempts which did not produce results are also necessary while esketamine, IV ketamine, ECT or rTMS"

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Interleaved TMS-fMRI in Ultra-treatment Resistant Depression

Dr. Sean Michael Nestor 2023. "Interleaved TMS-fMRI in Ultra-treatment Resistant Depression". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05813093.